Why the study?
Anticancer therapies carry risks of drug-drug interactions with direct oral anticoagulants leading to bleeding or recurrent thrombosis, but the best management strategies remain unclear.
Does concurrent administration of anticancer therapies and direct oral anticoagulants increase the risk of clinically relevant bleeding or thrombotic complications in patients with cancer?
Does concurrent administration of anticancer therapies and direct oral anticoagulants increase the risk of clinically relevant bleeding or thrombotic complications in patients with cancer?
This narrative review demonstrates that despite theoretical pharmacokinetic interactions via CYP3A4 and P-gp pathways, existing human clinical studies largely support the safe co-administration of direct oral anticoagulants with most interacting anticancer therapies without increased bleeding or thrombotic events.
Answers are grounded in this paper and cite their sources.
Clinicians must individualize DOAC therapy to balance bleeding-thrombosis risks with anticancer agents; leaves open optimal management strategies.
Patients with cancer have an increased risk of thrombosis requiring anticoagulation. Direct oral anticoagulants have become the primary anticoagulant of choice in most patients with cancer. Patients with cancer also receive many concomitant medications, including anticancer therapies with potential risks of drug-drug interactions with anticoagulants that can lead to concerns of bleeding or recurrent thrombosis. The best management strategies remain unclear. In this article, we aim to review the available literature pertaining to pharmacokinetic interactions between anticancer therapies and direct oral anticoagulants and provide guidance based on the evidence.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: